Turn Therapeutics (NasdaqGM:TTRX) FY Conference Transcript

Summary of Turn Therapeutics FY Conference Call Company Overview - Company: Turn Therapeutics (NasdaqGM:TTRX) - CEO: Bradley Burnam - Industry: Biotechnology, specifically focused on dermatological treatments Key Points and Arguments Company Background - Turn Therapeutics was founded by a former medical device representative who experienced chronic wounds and identified a gap in wound care products, leading to the development of their lead asset, GX-03 [2][4][5] - The company has developed a novel polymer-based formulation, utilizing a process called PermaFusion, which enhances bioavailability of active pharmaceutical ingredients (APIs) [5][6] Product Pipeline - Lead Asset: GX-03, a novel IL-36 and IL-31 inhibitor, currently in Phase 2 trials for moderate to severe eczema with expected interim results in Q2 2026 [7][14] - Onychomycosis Drug: A Phase 3 ready drug for toenail fungus, showing 70%-85% efficacy in a clinical trial, with potential for a combined Phase 2b/3 trial due to recent FDA updates [8][18][19] - The company is exploring international markets for eczema treatments, noting that the U.S. is a second-tier market compared to countries like Sweden and Denmark [17] Clinical Data and Efficacy - In vivo studies demonstrated a 57% reduction in Investigator Global Assessment for eczema over 7 days, validating the clinical effect of the product [12] - The ongoing Phase 2 trial is designed to compare the efficacy of GX-03 against a vehicle control, with primary endpoints including the Eczema Area and Severity Index (EASI) [14][51] Market Opportunity - The eczema market is large, with a significant unmet need for effective treatments that are non-systemic and non-irritating [15][16] - The toenail fungus market is described as having low competition, with many patients not seeking treatment due to poor existing options [20] Financial and Operational Highlights - The company has raised a total of $21 million and operates with a low burn rate, utilizing extensive vendor relationships to manage costs [21][22] - Turn Therapeutics has a strong intellectual property portfolio with 7 families and 17 issued patents, providing coverage into the late 2040s [22][38] Future Directions - The company is considering additional indications for its products, including hidradenitis suppurativa and psoriasis, leveraging its understanding of IL-36 driven bioburden [60][61] - Plans to enhance awareness in the dermatology community through academic conferences and partnerships with dermatology key opinion leaders (KOLs) [63] Other Important Content - The CEO emphasized the importance of safety in eczema treatments, noting the lack of adverse events reported in previous studies [46] - The company is actively working to ensure compliance in clinical trials and maximize the efficacy of their treatments [67][70]